Enhertu
74K
Volume
+614%
Growth
exploding
About the Topic
Targeted cancer treatment composed of a monoclonal antibody (fam-trastuzumab) and a chemotherapy drug (topoisomerase I inhibitor). This HER2-directed antibody and topoisomerase inhibitor conjugate is designed to specifically target and treat HER2-positive cancers, offering a more focused approach compared to traditional chemotherapy. Enhertu is primarily intended for patients with HER2-positive cancers, including breast and gastric cancers, who may benefit from targeted therapy.
Enhertu was discovered on August 16th 2023 and it currently has a search volume of 74K with a growth of +614%.
Key Indicators
Growth
- Exploding
- Regular
- Peaked
Speed
- Exponential
- Constant
- Stationary
Seasonality
- High
- Medium
- Low
Volatility
- High
- Average
- Low
Members Only
Try Exploding Topics Pro
Get Free, Unlimited Access for 7 Days.
Categories
Save this topic and build your own trend dashboard.
Available with Exploding Topics Pro, try it now.
1.1M+ trends in our growing database.